GO:0001811 negative regulation of type I hypersensitivity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001811 describes any process that stops, prevents, or reduces the rate of type I hypersensitivity, the IgE- and mast cell-driven inflammatory response.
• Negative regulation of type I hypersensitivity is essential to prevent excessive allergic inflammation and tissue damage.
• Key regulatory mechanisms include suppression of type 2 immunity, lipid mediator balance, and control of alarmins such as IL-33.
• Dysregulation of this process contributes to asthma, allergic rhinitis, atopic dermatitis, and food allergy.
• Environmental factors such as diet, air pollution, and iron status modulate the negative regulation of type I hypersensitivity.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of regulatory genes in type I hypersensitivity.
Description
Type I hypersensitivity is an IgE-mediated inflammatory response that underlies allergic diseases such as asthma, allergic rhinitis, and anaphylaxis. The Gene Ontology term GO:0001811, negative regulation of type I hypersensitivity, refers to any process that stops, prevents, or reduces the rate of this response. This regulatory process is critical for maintaining immune homeostasis and preventing excessive allergic inflammation. Understanding its molecular players is essential for developing therapies that dampen allergic reactions without compromising protective immunity.
negative regulation of type I hypersensitivity At A Glance
| GO ID | GO:0001811 |
|---|---|
| GO term | negative regulation of type I hypersensitivity |
| Ontology | biological_process |
| Synonym | down regulation of type I hypersensitivity, down-regulation of type I hypersensitivity, downregulation of type I hypersensitivity, inhibition of type I hypersensitivity |
| Major function | Suppression of IgE-mediated allergic inflammatory responses |
| Related processes | Type 2 immunity, mast cell activation, lipid mediator signaling |
| Key cell types | Mast cells, basophils, ILC2s, Th2 cells, endothelial cells |
| Disease relevance | Asthma, allergic rhinitis, atopic dermatitis, food allergy |
What Is GO:0001811?
GO:0001811 is a biological process defined as any process that stops, prevents, or reduces the rate of type I hypersensitivity, a type of inflammatory response. It encompasses molecular and cellular events that suppress the initiation, amplification, or effector phase of IgE-dependent allergic inflammation.
Why Is negative regulation of type I hypersensitivity Important in Cell Biology?
Negative regulation of type I hypersensitivity is vital because unchecked allergic inflammation can lead to chronic tissue damage, airway remodeling, and life-threatening anaphylaxis. Elucidating the endogenous brakes on this response provides targets for therapeutic intervention in allergic diseases.
• Prevents excessive IgE-mediated mast cell degranulation and histamine release.
• Controls type 2 immune responses that drive allergic inflammation.
• Modulates lipid mediator balance to resolve allergic inflammation.
• Regulates alarmins such as IL-33 in endothelial cells during airway inflammation.
• Influenced by environmental factors like diet, pollution, and iron status.
• Dysregulation contributes to asthma, allergic rhinitis, and food allergy.
• Provides therapeutic targets for allergy and asthma.
• Essential for distinguishing harmless allergens from pathogens.
• Impacts public health through allergy prevalence and severity.
• Guides development of precision allergy treatments.
What Happens During negative regulation of type I hypersensitivity?
Suppression of Type 2 Immunity Initiation
In simple terms: This step stops the immune system from overreacting to allergens by blocking the activation of Th2 cells and ILC2s.
Negative regulation begins at the initiation of type 2 immune responses. Regulatory cytokines and transcription factors suppress the differentiation and effector functions of Th2 cells and group 2 innate lymphoid cells (ILC2s), which are central to type I hypersensitivity. This suppression prevents the production of IL-4, IL-5, and IL-13 that drive IgE class switching and eosinophilia.
Control of IgE Production and Mast Cell Activation
In simple terms: This step reduces the amount of IgE antibodies and prevents mast cells from releasing histamine.
Negative regulation reduces IgE synthesis by B cells and limits mast cell degranulation. Lipid mediators such as lipoxins and resolvins can inhibit mast cell activation and promote resolution of allergic inflammation. This checkpoint prevents the amplification loop of allergen-specific IgE and mast cell sensitization.
Regulation of Alarmins and Endothelial Activation
In simple terms: This step controls alarm signals like IL-33 that activate immune cells during allergic airway inflammation.
Endothelial cells can negatively regulate IL-33, an alarmin that activates ILC2s and mast cells. During allergic airway inflammation, suppression of IL-33 in endothelium reduces type 2 cytokine production and airway hyperreactivity. This endothelial control represents a tissue-specific brake on type I hypersensitivity.
Metabolic and Nutritional Modulation
In simple terms: Diet, pollution, and nutrients can change how strongly the body reacts to allergens.
Environmental and nutritional factors modulate negative regulation. Ultra-processed foods and air pollution can exacerbate allergic outcomes by impairing regulatory mechanisms. Conversely, iron status influences ILC2 metabolism and effector function, thereby affecting airway hyperreactivity. Diet and nutrition play a significant role in allergic disease modulation.
Key Genes Involved in GO:0001811 negative regulation of type I hypersensitivity
The following genes and proteins are involved in the negative regulation of type I hypersensitivity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL33 | Alarmin activating ILC2s and mast cells | Endothelial negative regulation during airway inflammation |
| IL4 | Cytokine driving Th2 differentiation and IgE class switching | Target for suppressing type 2 immunity |
| IL13 | Effector cytokine in allergic inflammation | Modulates airway hyperreactivity |
| IL5 | Eosinophil survival and activation | Therapeutic target in asthma |
| FOXP3 | Regulatory T cell transcription factor | Suppresses type 2 responses |
| GATA3 | Th2 master transcription factor | Inhibition reduces type I hypersensitivity |
| RORα | ILC2 transcription factor | Regulates ILC2 function |
| ALOX15 | Lipid mediator synthesis | Produces pro-resolving mediators |
| PTGS2 | Prostaglandin synthesis | Modulates allergic inflammation |
| TGFB1 | Regulatory cytokine | Suppresses Th2 and mast cell responses |
| IL10 | Anti-inflammatory cytokine | Inhibits type 2 immunity |
| FCER1A | High-affinity IgE receptor | Mast cell activation target |
| MS4A2 | Beta chain of IgE receptor | Mast cell signaling |
| TPSAB1 | Mast cell tryptase | Marker of mast cell activation |
| CPA3 | Mast cell carboxypeptidase | Mast cell granule component |
| HDC | Histidine decarboxylase | Histamine synthesis |
| HRH1 | Histamine receptor H1 | Mediates allergic symptoms |
How Is negative regulation of type I hypersensitivity Regulated?
Negative regulation of type I hypersensitivity is controlled by a network of cytokines (IL-10, TGF-β), regulatory T cells, lipid mediators (lipoxins, resolvins), and metabolic cues such as iron availability. These regulators act at multiple checkpoints to suppress IgE production, mast cell activation, and type 2 cytokine signaling.
negative regulation of type I hypersensitivity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL33 | Asthma, allergic airway inflammation | Endothelial-specific knockout mouse |
| IL4 | Allergic asthma, atopic dermatitis | IL4 knockout or overexpression mouse |
| FOXP3 | Immune dysregulation, allergy | Foxp3 knockout mouse |
| ALOX15 | Allergic inflammation resolution | Alox15 knockout mouse |
| RORα | Airway hyperreactivity | ILC2-specific Rora knockout |
Asthma and Allergic Airway Inflammation
Impaired negative regulation of type I hypersensitivity contributes to asthma pathogenesis. Air pollution and ultra-processed foods can exacerbate airway inflammation by disrupting regulatory mechanisms. Iron status influences ILC2 metabolism and airway hyperreactivity, highlighting metabolic control of this process.
Food Allergy and Atopic Dermatitis
Diet and nutrition play a significant role in allergic diseases including food allergy and atopic dermatitis. Ultra-processed food consumption is associated with increased allergy outcomes in children, potentially through impairment of negative regulatory pathways.
Allergic Rhinitis and Anaphylaxis
Defective suppression of mast cell activation can lead to severe allergic reactions. Lipid mediators that negatively regulate type I hypersensitivity are potential therapeutic targets for allergic rhinitis and anaphylaxis.
From negative regulation of type I hypersensitivity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X suppress IgE production? | B cell-specific knockout |
| Does point mutation in gene Y alter mast cell degranulation? | Knock-in point mutation |
| Does overexpression of gene Z reduce airway inflammation? | Transgenic overexpression |
| Does tagged protein localize to mast cell granules? | Tagged knock-in |
| Does gene deletion affect ILC2 function? | ILC2-specific knockout |
| Does regulatory element control gene expression? | CRISPRi/CRISPRa |
How to Study the negative regulation of type I hypersensitivity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identifying regulatory networks |
| Lipidomics | Lipid mediator levels | Assessing pro-resolving mediators |
| Co-IP | Protein interactions | Mapping regulatory complexes |
| Flow cytometry | Immune cell populations | Quantifying Th2, ILC2, mast cells |
| ELISA | Cytokine and IgE levels | Measuring allergic responses |
| Histology | Tissue inflammation | Airway remodeling assessment |
| CRISPR screening | Gene function at scale | Discovering negative regulators |
Transcriptomic Profiling
RNA-seq of sorted immune cells (Th2, ILC2, mast cells) from knockout or overexpression models can identify gene networks involved in negative regulation of type I hypersensitivity.
Lipid Mediator Profiling
Mass spectrometry-based lipidomics measures pro-resolving mediators such as lipoxins and resolvins that negatively regulate allergic inflammation.
Protein-Protein Interaction Studies
Co-immunoprecipitation and proximity labeling can map interactions between regulatory proteins and signaling components in type I hypersensitivity.
In Vivo Allergy Models
Mouse models of allergic airway inflammation and passive cutaneous anaphylaxis assess the functional impact of candidate genes on type I hypersensitivity.
How CRISPR Can Be Used to Study GO:0001811 negative regulation of type I hypersensitivity
Knockout
CRISPR knockout of candidate negative regulators (e.g., IL33, FOXP3) in cell lines or primary immune cells can reveal their role in suppressing type I hypersensitivity.
Point Mutation
Introducing point mutations in genes such as FCER1A or MS4A2 can dissect signaling domains required for negative regulation of mast cell activation.
Knock-in
Knock-in of tagged versions of regulatory proteins (e.g., IL33-HA) enables tracking of their localization and interaction partners during allergic inflammation.
Overexpression
Overexpression of negative regulators like IL10 or TGFB1 in immune cells can test their capacity to suppress type 2 cytokine production and IgE synthesis.
How EDITGENE Supports negative regulation of type I hypersensitivity Research
Researchers studying negative regulation of type I hypersensitivity-related genes often need to determine whether a candidate gene is causally involved in suppressing allergic inflammation. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type I hypersensitivity research.
Frequently Asked Questions About negative regulation of type I hypersensitivity
What is negative regulation of type I hypersensitivity?
It is any process that stops, prevents, or reduces the rate of type I hypersensitivity, an IgE-mediated inflammatory response.
What genes are involved in negative regulation of type I hypersensitivity?
Key genes include IL33, IL4, IL13, FOXP3, GATA3, ALOX15, and TGFB1, among others.
How does negative regulation of type I hypersensitivity work?
It involves suppression of Th2 and ILC2 responses, reduced IgE production, inhibition of mast cell degranulation, and control of alarmins like IL-33.
What diseases are linked to defective negative regulation of type I hypersensitivity?
Asthma, allergic rhinitis, atopic dermatitis, food allergy, and anaphylaxis.
Can diet affect negative regulation of type I hypersensitivity?
Yes, diet and nutrition, including ultra-processed foods, can modulate allergic outcomes and regulatory mechanisms.
How does air pollution impact type I hypersensitivity?
Air pollution can exacerbate asthma and allergic inflammation by impairing negative regulatory pathways.
What is the role of iron in type I hypersensitivity?
Iron controls ILC2 metabolism and effector function, thereby influencing airway hyperreactivity.
How can CRISPR help study negative regulation of type I hypersensitivity?
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of candidate regulatory genes.
What cell types are important for negative regulation of type I hypersensitivity?
Mast cells, basophils, Th2 cells, ILC2s, regulatory T cells, and endothelial cells.
What are lipid mediators in type I hypersensitivity?
Lipid mediators such as lipoxins and resolvins can negatively regulate allergic inflammation and promote resolution.
Conclusion
Negative regulation of type I hypersensitivity (GO:0001811) is a critical biological process that restrains IgE-mediated allergic inflammation. Its dysregulation contributes to major allergic diseases, and understanding its molecular players offers therapeutic opportunities. CRISPR-based models and multi-omics approaches are powerful tools to dissect this process and identify new targets for allergy treatment.
References
- 1. Zhang P. 2023. The Role of Diet and Nutrition in Allergic Diseases.. Nutrients 15(17) PMID: 37686715
- 2. Berni Canani R et al.. 2024. Ultra-processed foods, allergy outcomes and underlying mechanisms in children: An EAACI task force report.. Pediatr Allergy Immunol 35(9):e14231 PMID: 39254357
- 3. Tiotiu AI et al.. 2020. Impact of Air Pollution on Asthma Outcomes.. Int J Environ Res Public Health 17(17) PMID: 32867076
- 4. de Kouchkovsky DA et al.. 2017. Negative Regulation of Type 2 Immunity.. Trends Immunol 38(3):154-167 PMID: 28082101
- 5. Nakamura T. 2021. The roles of lipid mediators in type I hypersensitivity.. J Pharmacol Sci 147(1):126-131 PMID: 34294363
- 6. Hurrell BP et al.. 2024. Iron controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function.. Sci Transl Med 16(746):eadk4728 PMID: 38718131
- 7. Romagnani S. 1994. Regulation of the development of type 2 T-helper cells in allergy.. Curr Opin Immunol 6(6):838-46 PMID: 7710707
- 8. Hollinger MK et al.. 2026. Negative regulation of human IL-33 in endothelium during allergic airway inflammation.. JCI Insight 11(9) PMID: 42100869
